Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2017—Molecular diagnostic device company iCubate has earned FDA clearance for its iCubate platform, the iC-System, and its first clinical assay, the iC-GPC Assay, used for the rapid detection of pathogenic bacteria associated with bloodstream infection.
November 2017—MilliporeSigma launched its Milli-Q HR 7000 series, a high-throughput water purification system that offers a uniquely connected and sustainable central pure water solution. The system ensures constant water quality and flow rate while reducing water consumption and running costs, as compared with other high-throughput reverse osmosis systems, and produces up to 13,000 liters of pure water daily.
November 2017—Quantimetrix announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for the company’s Dipper POCT Urinalysis Control. The patent application is directed to a liquid holding apparatus for insertion of a test device into a test liquid. The invention includes various technical innovations relating to the formation and use of an in vitro diagnostic pouch device.
November 2017—Denka Seiken has received FDA 510(k) clearance for its small, dense LDL cholesterol (sdLDL-C) assay, designed for use with automated chemistry analyzers.
November 2017—Binding Site’s Immunologicals Group has added two varicella zoster virus antigens to its line of products for in vitro diagnostic manufacturing and research applications. Both the standard VZV antigen and the VZV glycoprotein antigen have been designed for use as integral components within solid phase enzyme immunoassay test procedures.
November 2017—Aquaro Histology exhibited its AquaroASM, the company’s device for automating microtomy, at the 43rd Annual National Society for Histotechnology Symposium/Convention in September.
October 2017—Insight Pharma Reports has published Commercializing Novel IVDs: A Comprehensive Manual for Success by Harry Glorikian, MBA, who has more than 30 years in the global IVD field and in IVD innovation.
October 2017—North West London Pathology, hosted by Imperial College Healthcare NHS Trust, and Abbott have signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott’s Alinity ci and Alinity h series diagnostics instruments as well as its professional services and informatics solutions known as AlinIQ.
October 2017—sCMOS, with Sony’s Pregius CMOS sensor. The RT sCMOS is optimal for fluorescence microscopy, fluorescent in situ hybridization, green fluorescent protein (GFP) imaging, immunofluorescence, and 3-D deconvolution applications. Features include deep cooling, which allows dim images to be seen without becoming obscured by dark current; a global shutter, which ensures undistorted images of moving specimens; and 5 megapixel live and captured image resolution. The sCMOS is nine times more sensitive than the previous RT camera.
October 2017—Grifols and Beckman Coulter have entered into an exclusive, long-term agreement for the global distribution of Grifols’ hemostasis instruments, reagents, and consumables. The companies anticipate first commercializing systems under this agreement in Europe in early 2018.
